November 11, 2008Circulation
Drug-Eluting or Bare-Metal Stenting in Patients With Diabetes Mellitus
Why the study?
Do drug-eluting stents reduce mortality, myocardial infarction, and revascularization compared to bare-metal stents in patients with diabetes mellitus undergoing percutaneous coronary intervention?
Population
5,051 adults with diabetes mellitus undergoing percutaneous coronary intervention with stenting between…
Comparison
Drug-eluting stents (DES) vs Bare-metal stents (BMS)
Design
Cohort
Follow-up
3 years
Authors
Discussion
Loading...
Member takes
Implication
DES may warrant preference over BMS in diabetic PCI; extends prior cohorts but leaves causal confirmation open.
Structured PICO
Do drug-eluting stents reduce mortality, myocardial infarction, and revascularization compared to bare-metal stents in patients with diabetes mellitus undergoing percutaneous coronary intervention?
P
Population
5,051 adults with diabetes mellitus undergoing percutaneous coronary intervention with stenting between April 1, 2003, and September 30, 2004, at acute care nonfederal hospitals in Massachusetts.
I
Intervention
Drug-eluting stents (DES)
C
Comparator
Bare-metal stents (BMS)
O
Outcome
Mortality, myocardial infarction, and target vessel revascularization at 3 yearshard clinical
In a real-world population of patients with diabetes mellitus, the use of drug-eluting stents was associated with significantly lower long-term rates of mortality, myocardial infarction, and revascularization compared to bare-metal stents.
Cite This Study
Garg et al. (2008) studied this question.